FGFR3 and breast cancer: Similar to FGFR3 fusion-positive BC, erdafitinib and quisinostat are also synergistic in UM-UC-14 cells (Fig. 7b), and the combination can also achieve stronger inhibition in cell viability, compared to each individual drug treatment (Fig. 7c).